WO2022230925A1 - 膿皮症改善剤 - Google Patents

膿皮症改善剤 Download PDF

Info

Publication number
WO2022230925A1
WO2022230925A1 PCT/JP2022/019043 JP2022019043W WO2022230925A1 WO 2022230925 A1 WO2022230925 A1 WO 2022230925A1 JP 2022019043 W JP2022019043 W JP 2022019043W WO 2022230925 A1 WO2022230925 A1 WO 2022230925A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyoderma
vitamin
weight
erythritol
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/019043
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
学之 朝比奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asupakku Co Ltd
Original Assignee
Asupakku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asupakku Co Ltd filed Critical Asupakku Co Ltd
Priority to JP2023517589A priority Critical patent/JPWO2022230925A1/ja
Publication of WO2022230925A1 publication Critical patent/WO2022230925A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the present invention relates to a pyoderma-ameliorating agent that effectively suppresses skin diseases in a simple, safe, and low-cost manner without relying on antibiotics.
  • Pyoderma is a general term for skin infections caused by pyogenic bacteria such as Staphylococcus aureus and Streptococcus.
  • pyogenic bacteria such as Staphylococcus aureus and Streptococcus.
  • skin diseases associated with pyoderma such as "papillary dermatitis”, “folliculitis bald”, “chronic pyoderma of the buttocks” and “hidradenitis suppurativa”. has been reported.
  • the most serious problem of pyoderma is companion animals represented by dogs and cats, and it is especially dogs that urgently need to establish a new treatment method for pyoderma.
  • the main causes of pyoderma in dogs are Staphylococcus pseudointermedius and Staphylococcus.
  • Non-Patent Document 1 schleiferi and other coagulase-positive staphylococci.
  • the toxins produced by staphylococci are aggravating factors, but this bacterium is a normal skin bacterium and is thought to cause infections secondary to some skin disorders or underlying diseases (Non-Patent Document 2).
  • Systemic antibiotics are often used to treat pyoderma in dogs.
  • the present invention has been made on the basis of these points, and its purpose is to provide a method for effectively suppressing skin diseases in a simple, safe, and low-cost manner without relying on antibiotics.
  • the purpose is to provide a disease improving agent.
  • the pyoderma ameliorating agent according to claim 1 of the present invention is characterized by containing erythritol or xylitol as an active ingredient.
  • the pyoderma-ameliorating agent according to claim 2 is the pyoderma-ameliorating agent according to claim 1, It is characterized by containing 0.1% to 15.0% by weight of erythritol or xylitol.
  • a pyoderma-ameliorating agent according to claim 3 is the pyoderma-ameliorating agent according to claim 2, which is characterized by containing 1.0% by weight to 15.0% by weight of erythritol or xylitol. .
  • a pyoderma-ameliorating agent according to claim 4 is characterized in that, in the pyoderma-ameliorating agent according to any one of claims 1 to 3, vitamin C or a vitamin C derivative is added.
  • a pyoderma-ameliorating agent according to claim 5 is characterized in that, in the pyoderma-ameliorating agent according to claim 4, vitamin B group or vitamin D group is added.
  • a pyoderma-ameliorating agent according to claim 6 is the pyoderma-ameliorating agent according to claim 4, wherein vitamin B group and vitamin D group are added.
  • the pyoderma-ameliorating agent according to claim 7 is characterized in that, in the pyoderma-ameliorating agent according to claim 4, it is for companion animals.
  • the pyoderma-ameliorating agent according to claim 8 is characterized in that, in the pyoderma-ameliorating agent according to claim 7, it is for dogs.
  • the pyoderma-ameliorating agent according to claim 9 is characterized in that, in the pyoderma-ameliorating agent according to claim 5, it is for companion animals.
  • the pyoderma-ameliorating agent according to claim 10 is characterized in that, in the pyoderma-ameliorating agent according to claim 9, it is for dogs.
  • the pyoderma-ameliorating agent according to claim 11 is characterized in that, in the pyoderma-ameliorating agent according to claim 6, it is for companion animals.
  • the pyoderma-ameliorating agent according to claim 12 is characterized in that, in the pyoderma-ameliorating agent according to claim 11, it is for dogs.
  • the pyoderma ameliorating agent according to claim 1 of the present invention since it contains erythritol or xylitol as an active ingredient, it does not rely on antibiotics, and can be used to treat pyoderma easily, safely, and at low cost. can be effectively suppressed.
  • the pyoderma-ameliorating agent according to claim 2 is the pyoderma-ameliorating agent according to claim 1, Since 0.1% to 15.0% by weight of erythritol or xylitol is contained, pyoderma can be suppressed more effectively.
  • the pyoderma-ameliorating agent according to claim 3 contains 1.0% by weight to 15.0% by weight of erythritol or xylitol in the pyoderma-ameliorating agent according to claim 2, it is more effective for pyoderma. can be effectively suppressed.
  • the pyoderma-ameliorating agent according to claim 4 is the pyoderma-ameliorating agent according to any one of claims 1 to 3, in which vitamin C or a vitamin C derivative is added, so that pyoderma is improved. can be effectively suppressed.
  • the pyoderma ameliorating agent according to claim 5 is the pyoderma ameliorating agent according to claim 4, in which vitamin B group or vitamin D group is added, so that pyoderma can be suppressed more effectively.
  • the pyoderma ameliorating agent according to claim 6 is the pyoderma ameliorating agent according to claim 4, in which vitamin B group and vitamin D group are added, so that pyoderma can be suppressed more effectively.
  • the pyoderma-ameliorating agent according to claim 7 is for companion animals in the pyoderma-ameliorating agent according to claim 4, it is possible to more effectively suppress pyoderma in companion animals.
  • the pyoderma-ameliorating agent according to claim 8 is the pyoderma-ameliorating agent according to claim 7, which is for dogs, pyoderma can be more effectively suppressed in dogs.
  • the pyoderma-ameliorating agent according to claim 9 is for companion animals in the pyoderma-ameliorating agent according to claim 5, pyoderma can be more effectively suppressed in companion animals.
  • the pyoderma-ameliorating agent according to claim 10 is the pyoderma-ameliorating agent according to claim 9, which is for dogs, pyoderma can be more effectively suppressed in dogs.
  • the pyoderma-ameliorating agent according to claim 11 is for companion animals in the pyoderma-ameliorating agent according to claim 6, it is possible to more effectively suppress pyoderma in companion animals.
  • the pyoderma-ameliorating agent according to claim 12 is the pyoderma-ameliorating agent according to claim 11, which is for dogs, pyoderma can be more effectively suppressed in dogs.
  • Fig. 10 is a photograph showing the results of Example 4 of the third embodiment of the present invention, showing a dog in which the pyoderma-ameliorating agent according to Formulation Example 29 was sprayed onto the affected area and the progress was observed.
  • Fig. 10 is a photograph showing the results of Example 4 of the third embodiment of the present invention, showing a dog in which the pyoderma-ameliorating agent according to Formulation Example 30 was sprayed onto the affected area and the progress was observed.
  • Fig. 10 is a photograph showing the results of Example 4 of the third embodiment of the present invention, showing a dog in which the pyoderma-ameliorating agent according to Formulation Example 30 was sprayed onto the affected area and the progress was observed.
  • the pyoderma ameliorating agent according to this first embodiment is an aqueous solution of erythritol or xylitol. Pyoderma is improved by applying the pyoderma-ameliorating agent to the affected area.
  • Erythritol used in the present invention is a tetravalent sugar alcohol, is contained in natural foods such as lichens, mushrooms, and fruits, and is a highly safe material. Methods for producing erythritol are divided into chemical synthesis methods and fermentation methods, but most of them are produced, for example, by fermentation with yeast using glucose as a raw material. Xylitol used in the present invention is produced, for example, by hydrogenating xylose.
  • the content of erythritol or xylitol in the agent for improving atopic dermatitis of the present invention is preferably 0.1 to 15% by weight, particularly preferably 1 to 10% by weight, based on the total amount of the composition. It has been found that if the amount is less than 1% by weight, the effect is reduced, but if the amount exceeds 10% by weight, the same effect is obtained, but the solubility is deteriorated, which is not preferable for the preparation of external preparations. If it is less than 0.1% by weight, no effect is observed. If the erythritol or xylitol content exceeds 15% by weight, it crystallizes and cannot be used as a pyoderma ameliorating agent.
  • Pyoderma is a skin disease that has been confirmed not only in humans but also in many animals (dogs, cats, horses, mice, etc.).
  • the mechanism of its onset is the transient proliferation of specific skin-resident bacteria, the toxins of which reduce the barrier function of the skin, and the invasion of bacterial metabolites and bacteria into the body, which induces inflammation.
  • living organisms to which the present invention can be applied include pets such as dogs, cats, horses, and mice, in addition to humans.
  • the pyoderma-ameliorating agent of the present invention When the pyoderma-ameliorating agent of the present invention is administered to a living body, it may be administered as it is, but it may be provided by blending it with a suitable additive in an external composition for skin as long as the effects of the present invention are not impaired. preferable.
  • the external preparation for skin of the present invention includes pharmaceuticals, quasi-drugs, cosmetics and the like.
  • the dosage form of pharmaceuticals, quasi-drugs, and cosmetics containing the pyoderma-ameliorating agent of the present invention is not particularly limited as long as it does not impair the effects of the present invention.
  • all formulations used for skin external preparations such as sprays, ointments, lotions and creams can be applied.
  • As the base used for these external preparations for skin a known base or a base that will be newly provided in the future may be used, and there is no particular limitation.
  • petrolatum, castor oil, silicone, squalane, sodium acrylate behenyl alcohol, glycerol monostearate, stearyl alcohol, ethanol, batyl alcohol, phenoxyethanol, 1,3-butylene glycol, isopropyl myristate, stearic acid, lecithin and purified water. and can be used singly or in combination of two or more.
  • the agent for improving pyoderma of the present invention includes, in addition to the base components described above, various components acceptable in the production of pharmaceuticals, quasi-drugs, and cosmetics within a range that does not impair the effects of the present invention, i.e., antioxidants.
  • Additives such as , preservatives, wetting agents, thickeners, buffers, adsorbents, solvents, emulsifiers and stabilizers can be added as appropriate.
  • the "improving effect on pyoderma” refers to the characteristic symptoms of pyoderma such as skin inflammation, red eruption, It means an improvement effect that can be brought about as a skin external preparation, such as improvement of pustules (pimples), dry skin, hair loss, and the like.
  • the present invention is a pyoderma-ameliorating agent containing erythritol or xylitol as an active ingredient, and erythritol or xylitol is not a medicinal ingredient and is also incorporated in commonly distributed cosmetics, health foods, and general foods. Because it is a component that has been approved, it is safe and highly effective because it has few side effects like antibacterial agents and problems such as multidrug-resistant bacteria. In addition, it can be used simply by applying it to the affected area as an external preparation for the skin.
  • Formulation Example 1 contains 0.1% by weight of erythritol.
  • Formulation Example 2 contains 0.5% by weight of erythritol.
  • Formulation Example 3 contains 1% by weight of erythritol.
  • Formulation Example 4 contains 5% by weight of erythritol.
  • Formulation Example 5 contains 10% by weight of erythritol.
  • Formulation Example 6 contains 12% by weight of erythritol.
  • Formulation Example 7 contains 15% by weight of erythritol.
  • Formulation Example 1 contains 0.1% by weight of xylitol.
  • Formulation Example 8 contains 0.1% by weight of xylitol.
  • Formulation 9 contains 1% by weight of xylitol.
  • Formulation Example 10 contains 5% by weight of xylitol.
  • Formulation Example 5 contains 10% by weight of xylitol.
  • Formulation 11 contains 10% by weight of xylitol.
  • Formulation 12 contains 15% by weight of xylitol. As described above, if the erythritol content exceeds 15% by weight, the erythritol crystallizes and cannot be used as a pyoderma ameliorating agent.
  • comparative formulation examples 1 to 3 were prepared as objects for comparison.
  • Comparative Formulation Example 1 (Component) (% by weight) Propanediol 5.0 Glycerin 2.0 purified water residue
  • Comparative prescription example 2 (Component) (% by weight) Sorbitol 10.0 Propanediol 5.0 Glycerin 2.0 purified water residue
  • Comparative prescription example 3 (Component) (% by weight) Magnesium ascorbyl phosphate 0.05 Propanediol 5.0 Glycerin 2.0 purified water residue
  • Erythritol is not contained in Comparative Formulation Example 1.
  • Comparative Formulation Example 2 instead of erythritol, sorbitol, which is one of the sugar alcohols in the category of carbohydrates to which erythritol is classified, is blended.
  • Comparative Formulation Example 3 contained only magnesium ascorbyl phosphate.
  • the dog's mean pyoderma severity score (PyodermaSCORE) was 5.45 ⁇ 1.64.
  • the dogs used in the test were mostly Toy Poodles, Shih Tzu, Shiba Inu, Maltese, Pomeranian, Jack Russell Terrier, etc., including small to large dogs, and individuals from 1 to 10 years old. was targeted.
  • PyodermaSCORE Pyoderma ScoRE
  • Table 1 shows the criteria for the pyoderma severity score.
  • the sum of the scores according to the "criterion of degree of disease” and the score according to “criterion of range of disease” shown in Table 1 is the pyoderma severity score.
  • a spray bottle was filled with each of the solutions shown in Formulation Examples and Comparative Formulation Examples, and 2 to 3 mL per push was applied to the affected area 3 to 5 times a day, and the effect was verified after 2 weeks.
  • the above-mentioned pyoderma severity score (PyodermaSCORE) was used to score the degree of improvement of pyoderma.
  • Table 2 shows the evaluation results of Formulation Examples 1 to 7
  • Table 3 shows the evaluation results of Formulation Examples 8 to 12
  • Table 4 shows the evaluation results of Comparative Formulation Examples 1 to 3.
  • EXCELLENTS Individuals whose score after the end of the test decreased by 20% or more from the score before the start of the test
  • GOOD Individual FAIR whose score after the end of the study decreased by 10% or more and less than 20% from the score before the start of the study:
  • Individual POOR whose score after the end of the test decreased from 0% to less than 10% from the score before the start of the test:
  • an individual whose score after the end of the test decreased by 10% or more from the score before the start of the test (EXCELLENT + GOOD) was regarded as an individual with improvement, and the improvement rate (%) was calculated by the following formula.
  • Improvement rate (%) ⁇ (number of individuals showing improvement) / (number of individuals used in test) ⁇ x 100
  • the pyoderma improving agent according to the second embodiment is obtained by adding vitamin C or a vitamin C derivative to an aqueous solution of erythritol or xylitol. , which improves pyoderma.
  • vitamin C examples include ascorbic acid, and examples of vitamin C derivatives include salts of vitamin C (sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt, etc.).
  • Vitamin C derivatives that can be preferably used in the present invention include, more specifically, for example, magnesium ascorbyl phosphate, trisodium ascorbyl palmitate phosphate, sodium ascorbate phosphate, aminoprolyl ascorbate phosphate, glucoside ascorbate, and palmitin.
  • Example 2 Formulation Examples 13 to 16 of pyoderma-ameliorating agents used in the test are shown below. In addition, the unit is described in terms of the compounding amount (% by weight) in the agent per 100 mL.
  • Formulation Example 13 contains 5.0% by weight of erythritol and 0.05% by weight of ascorbic acid as vitamin C.
  • Formulation Example 14 contains 5.0% by weight of erythritol and 0.05% by weight of magnesium ascorbyl phosphate as a vitamin C derivative.
  • Formulation Example 15 contains 5.0% by weight of xylitol and 0.05% by weight of ascorbic acid as vitamin C.
  • Formulation Example 16 contains 5.0% by weight of xylitol and 0.05% by weight of magnesium ascorbyl phosphate as a vitamin C derivative.
  • Table 5 shows the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agents according to Formulation Examples 13 and 14 above.
  • Table 6 shows the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agent according to No. 16.
  • Formulation Example 17 contains 5.0% by weight of erythritol and 0.5% by weight of magnesium ascorbyl phosphate as a vitamin C derivative.
  • Formulation Example 18 contains 5.0% by weight of erythritol and 2.5% by weight of magnesium ascorbyl phosphate as a vitamin C derivative.
  • Formulation Example 19 contains 5.0% by weight of erythritol and 5.0% by weight of magnesium ascorbyl phosphate as a vitamin C derivative.
  • Formulation Example 20 contains 5.0% by weight of erythritol and 10.0% by weight of magnesium ascorbyl phosphate as a vitamin C derivative.
  • Table 7 shows the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agents according to Formulation Examples 17 to 20 above.
  • erythritol, xylitol, the above-mentioned vitamin C and vitamin C derivatives are not pharmaceutical ingredients, but are ingredients contained in commonly distributed cosmetics, health foods, and general foods. can be reduced.
  • the pyoderma ameliorating agent according to the third embodiment is obtained by adding vitamin C or a vitamin C derivative to an aqueous solution of erythritol or xylitol, and adding vitamins of the vitamin B group and/or the vitamin D group. is added.
  • B vitamins include vitamin B1, vitamin B2, niacin (nicotinic acid and nicotinamide), pantothenic acid, panthenol, vitamin B6 (pyridoxine, pyridoxal and pyridoxamine), biotin, folic acid and vitamin B12 (cyanocobalamin, hydroxo cobalamin, methylcobalamin and adenosylcobalamin).
  • the vitamin D group includes, for example, cholecalciferol (vitamin D3), ergocalciferol (vitamin D2), dihydrocalciferol, dihydrotachysterol, alfacalcidol, calcitriol and the like.
  • the pyoderma-ameliorating agent according to the third embodiment can obtain a higher pyoderma-ameliorating effect.
  • vitamin C derivative ascorbyl magnesium phosphate Showa Denko K.K.'s ascorbic acid PS as vitamin C derivative as ascorbyl sodium phosphate, vitamin C derivative Showa Denko Co., Ltd.'s Ascofresh (registered trademark) as ascorbic acid 2-glucoside, a vitamin C derivative, and Fuji Film Wako Jun as vitamin C ascorbic acid.
  • "L-ascorbyl magnesium phosphate” manufactured by Pharmaceutical Co., Ltd., "D-pantothenyl alcohol” manufactured by DSM Co., Ltd. as vitamin B panthenol, and "cholecalciferol” manufactured by Tokyo Chemical Industry Co., Ltd. as vitamin D cholecalciferol "It was used.
  • purified water tap water or underground water filtered with a membrane filter was used.
  • Tables 8 and 9 show the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agents according to Formulation Examples 21 to 24 above.
  • Formulation Example 21 containing 5% erythritol, 0.05% ascorbic acid (vitamin C) and 0.05% vitamin B group (panthenol) has an improvement rate of 91.7%
  • Formulation Example 22 5% erythritol and vitamins Those containing 0.05% C derivative (magnesium ascorbyl phosphate) and 0.05% B vitamins (panthenol) had an improvement rate of 91.7%
  • Formulation Example 23 containing 5% xylitol, 0.05% ascorbic acid (vitamin C) and 0.05% B vitamins (panthenol) showed an improvement rate of 90%
  • Formulation Example 24 containing 5% xylitol and a vitamin C derivative. The one containing 0.05% (magnesium ascorbyl phosphate) and 0.05% B vitamins (panthenol) had an improvement rate of 90%.
  • Tables 10 and 11 show the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agents according to Formulation Examples 25 to 28 above.
  • Formulation Example 25 containing 5% erythritol, 0.05% ascorbic acid (vitamin C) and 0.05% vitamin D group (cholecalciferol) showed an improvement rate of 85.7%, and Formulation Example 26 containing 5% erythritol.
  • Formulation Example 27 which contains 5% xylitol, 0.05% ascorbic acid (vitamin C), and 0.05% vitamin D group (cholecalciferol), has an improvement rate of 84.6%, and 5% xylitol in Formulation Example 28. The improvement rate was 88.9% with 0.05% vitamin C derivative (magnesium ascorbyl phosphate) and 0.05% vitamin D group (cholecalciferol).
  • Tables 12 and 13 show the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agents according to Formulation Examples 29 to 32 above.
  • Table 14 shows the results of the same experiment as in Example 1 of the first embodiment using the pyoderma-ameliorating agents according to Formulation Examples 33 to 35 above.
  • Formulation Example 33 containing 5% erythritol, sodium ascorbyl phosphate (0.05% vitamin C derivative, 0.05% vitamin B group (panthenol), and 0.05% vitamin D group (cholecalciferol) improved Erythritol 5% of Formulation Example 34, vitamin C derivative (trisodium ascorbyl palmitate phosphate) 0.05%, vitamin B group (panthenol) 0.05% and vitamin D group (cholecalciferol) Those containing 0.05% had an improvement rate of 91.7%.
  • FIG. 1 to 3 show representative clinical photographs of individuals showing an improvement effect among the results of this test.
  • FIG. 1 is a photograph of a dog before prescription of Formulation Example 29 and 40 days after the prescription.
  • FIG. 2 is a photograph of a dog before prescription of Formulation Example 30 and 30 days after the prescription.
  • FIG. 3 is a photograph of a dog before prescription of Formulation Example 30 and 20 days after the prescription. Moreover, no side effects due to application were observed in the formulation examples.
  • erythritol, xylitol, vitamin C, vitamin C derivatives, vitamin B group, and vitamin D group are not pharmaceutical ingredients, but ingredients that are blended in commonly distributed cosmetics, health foods, and general foods. Adverse effects such as side effects on the skin can be reduced.
  • the present invention relates to pyoderma-ameliorating agents, and in particular to those devised to effectively suppress pyoderma in a simple, safe, and low-cost manner without relying on antibiotics. , suitable as a pyoderma-improving agent for dogs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2022/019043 2021-04-28 2022-04-27 膿皮症改善剤 Ceased WO2022230925A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023517589A JPWO2022230925A1 (https=) 2021-04-28 2022-04-27

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021075797 2021-04-28
JP2021-075797 2021-04-28

Publications (1)

Publication Number Publication Date
WO2022230925A1 true WO2022230925A1 (ja) 2022-11-03

Family

ID=83848520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/019043 Ceased WO2022230925A1 (ja) 2021-04-28 2022-04-27 膿皮症改善剤

Country Status (2)

Country Link
JP (1) JPWO2022230925A1 (https=)
WO (1) WO2022230925A1 (https=)

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138125A (ja) * 1993-11-19 1995-05-30 Shiseido Co Ltd 皮膚外用剤
WO1999024043A1 (en) * 1997-11-07 1999-05-20 Medion Research Laboratories Inc. Viscous compositions containing carbon dioxide
JP2000302674A (ja) * 1999-04-22 2000-10-31 Shiseido Co Ltd 選択的抗菌組成物
JP2000302673A (ja) * 1999-04-22 2000-10-31 Shiseido Co Ltd アトピー性皮膚炎用皮膚外用剤
JP2000319187A (ja) * 1999-05-06 2000-11-21 Medion Research Laboratories Inc 二酸化炭素経皮・経粘膜吸収用組成物
JP2001172150A (ja) * 1999-12-20 2001-06-26 Mareyoshi Sawaguchi 口腔用及び外用薬組成物
WO2002080941A1 (en) * 2001-04-06 2002-10-17 Masaya Tanaka Compositions for preparing external carbon dioxide agents
WO2005016290A1 (ja) * 2003-08-19 2005-02-24 Neochemir Inc. 二酸化炭素外用ゲル調製用組成物と二酸化炭素外用ゲル
JP2005225830A (ja) * 2004-02-16 2005-08-25 Shiseido Co Ltd 皮膚外用組成物
JP2008526827A (ja) * 2005-01-07 2008-07-24 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタエンの速崩壊性投与形態
CN101746906A (zh) * 2008-12-03 2010-06-23 五邑大学 一种含重金属离子电镀废水的处理方法
JP2013100267A (ja) * 2011-10-11 2013-05-23 Daiichi Sankyo Healthcare Co Ltd ビタミン類を含有する抗炎症のための皮膚外用剤組成物
JP2015514715A (ja) * 2012-03-30 2015-05-21 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド コルヒチン製剤、その製造方法および使用方法
US20170027881A1 (en) * 2015-07-30 2017-02-02 Neil A. Shah Composition and related methods for treatment of pilosebaceous diseases
JP2018030852A (ja) * 2012-08-07 2018-03-01 トレル、 ジャン ノエル 皮膚アトピーの美容的治療におけるステアリン酸スクロースおよび／またはソルビタンエステルによる病原微生物の接着阻害
CN109010294A (zh) * 2018-08-27 2018-12-18 邓倩 一种头孢妥仑匹酯片剂的生产工艺
JP2020525460A (ja) * 2017-06-27 2020-08-27 ロッタファーム エスピーエーＲｏｔｔａｐｈａｒｍ ＳＰＡ 皮膚科治療におけるガラクトオリゴ糖およびキシリトールの抗菌活性
WO2021023695A1 (en) * 2019-08-02 2021-02-11 MEDA Pharma S.p.A. Combinations of oligosaccharides and xylitol for dermatological treatment
CN112402391A (zh) * 2020-12-16 2021-02-26 湖北凌晟药业有限公司 一种头孢卡品酯颗粒剂及其制备方法
WO2022053952A1 (en) * 2020-09-08 2022-03-17 Apr Applied Pharma Research S.A. Dermal compositions replicating the vernix caseosa

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138125A (ja) * 1993-11-19 1995-05-30 Shiseido Co Ltd 皮膚外用剤
WO1999024043A1 (en) * 1997-11-07 1999-05-20 Medion Research Laboratories Inc. Viscous compositions containing carbon dioxide
JP2000302674A (ja) * 1999-04-22 2000-10-31 Shiseido Co Ltd 選択的抗菌組成物
JP2000302673A (ja) * 1999-04-22 2000-10-31 Shiseido Co Ltd アトピー性皮膚炎用皮膚外用剤
JP2000319187A (ja) * 1999-05-06 2000-11-21 Medion Research Laboratories Inc 二酸化炭素経皮・経粘膜吸収用組成物
JP2001172150A (ja) * 1999-12-20 2001-06-26 Mareyoshi Sawaguchi 口腔用及び外用薬組成物
WO2002080941A1 (en) * 2001-04-06 2002-10-17 Masaya Tanaka Compositions for preparing external carbon dioxide agents
WO2005016290A1 (ja) * 2003-08-19 2005-02-24 Neochemir Inc. 二酸化炭素外用ゲル調製用組成物と二酸化炭素外用ゲル
JP2005225830A (ja) * 2004-02-16 2005-08-25 Shiseido Co Ltd 皮膚外用組成物
JP2008526827A (ja) * 2005-01-07 2008-07-24 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタエンの速崩壊性投与形態
CN101746906A (zh) * 2008-12-03 2010-06-23 五邑大学 一种含重金属离子电镀废水的处理方法
JP2013100267A (ja) * 2011-10-11 2013-05-23 Daiichi Sankyo Healthcare Co Ltd ビタミン類を含有する抗炎症のための皮膚外用剤組成物
JP2015514715A (ja) * 2012-03-30 2015-05-21 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド コルヒチン製剤、その製造方法および使用方法
JP2018030852A (ja) * 2012-08-07 2018-03-01 トレル、 ジャン ノエル 皮膚アトピーの美容的治療におけるステアリン酸スクロースおよび／またはソルビタンエステルによる病原微生物の接着阻害
US20170027881A1 (en) * 2015-07-30 2017-02-02 Neil A. Shah Composition and related methods for treatment of pilosebaceous diseases
JP2020525460A (ja) * 2017-06-27 2020-08-27 ロッタファーム エスピーエーＲｏｔｔａｐｈａｒｍ ＳＰＡ 皮膚科治療におけるガラクトオリゴ糖およびキシリトールの抗菌活性
CN109010294A (zh) * 2018-08-27 2018-12-18 邓倩 一种头孢妥仑匹酯片剂的生产工艺
WO2021023695A1 (en) * 2019-08-02 2021-02-11 MEDA Pharma S.p.A. Combinations of oligosaccharides and xylitol for dermatological treatment
WO2022053952A1 (en) * 2020-09-08 2022-03-17 Apr Applied Pharma Research S.A. Dermal compositions replicating the vernix caseosa
CN112402391A (zh) * 2020-12-16 2021-02-26 湖北凌晟药业有限公司 一种头孢卡品酯颗粒剂及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IYORI KEITA, HASHIMOTO SENJU, KAWANO KOJI, TOCHIO TAKUMI, HIROOKA YOSHIKI; MIYAHARA RYOJI: "Proposal of new treatments to solve the issue of drug-resistant bacteria in superficial pyoderma in dogs", CAP. COMPANION ANIMAL PRACTICE - KONPANION, ANIMARU, PURAKUTISU, CHIKUSAN SHUPPANSHA, TOKYO, JP, vol. 36, no. 6, 1 June 2021 (2021-06-01), JP , pages 76 - 79, XP009540692, ISSN: 0913-5316 *
KURIKI YASUHIRO, SEIKI SATO : "A Case of Dermatitis Papillaris Capillitii", SKIN RESEARCH, vol. 42, no. 1, 1 January 2000 (2000-01-01), pages 97 - 100, XP055982833, DOI: 10.11340/skinresearch1959.42.97 *
KURIKI YASUHIRO, SHOICHIRO MINAMI, KEIKO KITAGAWA, YUKIO KITANO, YASUTSUGU SHOJI, HIROKI NAKANO, TAKEHIRA YAMAMURA: "A Case of Chronic Perianal Pyoderma", SKIN RESEARCH, vol. 41, no. 2, 1 January 1999 (1999-01-01), pages 195 - 198, XP055982834, DOI: 10.11340/skinresearch1959.41.195 *
TAMURA, YUKIO ET AL.: "Bacterial Spectrum detected in Dogs with Pyoderma", NIPPON JUISHIKAI ZASSHI - JOURNAL OF THE VETERINARY MEDICALASSOCIATION, NIPPON JUISHIKAI, TOKYO,, JP, vol. 46, 1 January 1993 (1993-01-01), JP , pages 54 - 56, XP009540693, ISSN: 0446-6454 *

Also Published As

Publication number Publication date
JPWO2022230925A1 (https=) 2022-11-03

Similar Documents

Publication Publication Date Title
US7262180B2 (en) Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye
US20080194664A1 (en) Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea
US20150011490A1 (en) Treatment of papulopustular rosacea with ivermectin
US20140056990A1 (en) Composition for the treatment of migraine headaches and methods thereof
US12478681B2 (en) Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals
US8431601B2 (en) Topical compositions comprising telmesteine for treating dermatological disorders
US9125927B2 (en) Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea
US20210128548A1 (en) External preparation comprising pyridonecarboxylic acid derivative
WO2022230925A1 (ja) 膿皮症改善剤
US20110256237A1 (en) Methods and compositions for treating acne vulgaris and acne rosacea
WO2022138866A1 (ja) アトピー性皮膚炎改善剤
TW201622712A (zh) 外用醫藥組成物
CA2479381C (en) A use of treatment for fungal infections with a synergistic formulation of antifungal agent, menthol and menthyl acetate
KR20180135169A (ko) 퀘르세틴 및 비타민 d를 함유하는 여드름 피부 개선용 조성물
JP2024128672A (ja) 顔の皮膚状態の改善剤
WO2024166108A1 (en) Method of treating skin condition or disease
US20200146983A1 (en) Enhanced antibiotic and drug delivery for aqueous topical applications for human and veterinary uses
US20230099068A1 (en) Topical antimicrobial formulations
EP3738588A1 (en) Topical and oral formulations comprising taurine and magnesium for use in the treatment of rosacea
US20190262390A1 (en) Topical and oral formulations comprising taurine and magnesium for the treatment of rosacea
JP2006219411A (ja) エッセンス剤形の皮膚外用剤
DE202008000654U1 (de) Zusammensetzung zur Behandlung von Haut-, Haar- und Nagelerkrankungen und -problemen
LV14644B (lv) Krēms psoriāzes izraisītu patoloģisku ādas izmaiņu ārstēšanai

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22795838

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023517589

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22795838

Country of ref document: EP

Kind code of ref document: A1